Evaxion Biotech Management
Management criteria checks 3/4
Evaxion Biotech's CEO is Christian Kanstrup, appointed in Sep 2023, has a tenure of 1.25 years. total yearly compensation is $373.00K, comprised of 31.1% salary and 68.9% bonuses, including company stock and options. directly owns 1.32% of the company’s shares, worth $65.79K. The average tenure of the management team and the board of directors is 2.3 years and 3.8 years respectively.
Key information
Christian Kanstrup
Chief executive officer
US$373.0k
Total compensation
| CEO salary percentage | 31.1% |
| CEO tenure | 1.3yrs |
| CEO ownership | 1.3% |
| Management average tenure | 2.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27
We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$11m |
| Jun 30 2024 | n/a | n/a | -US$15m |
| Mar 31 2024 | n/a | n/a | -US$15m |
| Dec 31 2023 | US$373k | US$116k | -US$22m |
Compensation vs Market: Christian's total compensation ($USD373.00K) is below average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Insufficient data to compare Christian's compensation with company performance.
CEO
Christian Kanstrup (52 yo)
1.3yrs
Tenure
US$373,000
Compensation
Mr. Christian Kanstrup, MSc, serves as Chief Executive Officer of Evaxion Biotech A/S since September 01, 2023. He joined Evaxion Biotech A/S on September 01, 2023. He previously served as Executive Vice P...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.3yrs | US$373.00k | 1.32% $ 65.8k | |
| Founder & Chief AI Officer | 16.9yrs | US$246.00k | 7.68% $ 383.5k | |
| Chief Scientific Officer | 3.3yrs | US$269.00k | 0.066% $ 3.3k | |
| Chief Financial Officer | less than a year | no data | no data |
2.3yrs
Average Tenure
50yo
Average Age
Experienced Management: EVAX's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 3.6yrs | US$64.00k | 0.13% $ 6.6k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Chairwoman of the Board | 4.1yrs | US$193.00k | 1.46% $ 73.1k | |
| Independent Director | 6.9yrs | US$68.00k | 0.72% $ 36.0k | |
| Director | less than a year | US$407.00k | 0.066% $ 3.3k |
3.8yrs
Average Tenure
56yo
Average Age
Experienced Board: EVAX's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 16:27 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evaxion Biotech A/S is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Ahu Demir | Ladenburg Thalmann & Company |
| Thomas Flaten | Lake Street Capital Markets, LLC |